Industry and Satellite CME Symposia(TEST) - IASLC 2021 WCLC World Conference on Lung Cancer

San Francisco

Denver

Rome

Sydney

IS01 - Satellite CME Symposium Sponsored by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Date: Thursday, January 28, 2021 | Time: 09:15 – 10:15 SGT

Chairs/Speakers: TBD

Agenda

Welcome, Introduction, Polling Questions

Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC
Dr. Ross Camidge, MD, PhD

Activity of ADCs in Clinical Trials for Lung Cancer
Dr. Joel W. Neal, MD, PhD

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
All

Audience Q&A, Panel Discussion

IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
Date: Thursday, January 28, 2021 | Time: 10:30 - 11:30 SGT

Chairs/Speakers: John Heymach (USA), Masahiro Tsuboi (Japan), Myung-Ju Ahn (S Korea), Glenwood Goss (Canada), Charles Rudin (USA), Suresh Senan (The Netherlands)

Agenda
10:30 SGT	Opening Remarks Masahiro Tsuboi
10:35 SGT	Current Strategies for IO Therapy for Unresectable Stage III NSCLC Glenwood Goss
10:45 SGT	Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC Suresh Senan
10:55 SGT	Defining the Role of Immunotherapy in the Treatment of ES-SCLC Myung-Ju Ahn
11:05 SGT	Emerging Biomarkers in SCLC Charles Rudin
11:15 SGT	Panel Discussion / Q&A All

IS03 - Industry Symposium Sponsored by Daiichi Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
Date: Thursday, January 28, 2021 | Time: 11:45 - 12:45 SGT

Chairs/Speakers: Tony Mok (Hong Kong SAR), Pasi Jänne (USA), James Yang (Taiwan)

Agenda
11:45 SGT	Welcome and Introduction Tony Mok
11:50 SGT	Evolving challenges for the treatment of advanced NSCLC Tony Mok
12:00 SGT	Emerging ADC targets for the treatment of late-line NSCLC Pasi Jänne
12:15 SGT	ADC therapies as targeted treatment options in patients with advanced NSCLC James Yang
12:30 SGT	Interactive Q+A/Panel Discussion All

IS04 - Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
Date: Thursday, January 28, 2021 | Time: 13:00 - 14:00 SGT

Chairs/Speakers: Koichi Goto (Japan), Herbert Loong (Hong Kong SAR), Fernando López-Ríos (Spain), Giuseppe Curigliano (Italy)

Agenda
13:00 SGT	Chair’s Welcome Koichi Goto
13:04 SGT	Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC Koichi Goto
13:10 SGT	Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC – Practical tips on optimising diagnostic capabilities in the clinic Herbert Loong
13:22 SGT	The roles of the Oncologist and Pathologist in providing an actionable diagnosis – Discuss the role of the Tumour Board / MDT in implementing precision medicine Fernando López-Ríos
13:34 SGT	Gaining consensus – An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\ Giuseppe Curigliano
13:44 SGT	Panel discussion and Q&A All
14:00 SGT	Symposium close Koichi Goto

IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
Date: Thursday, January 28, 2021 | Time: 14:15 - 15:15 SGT

Chairs/Speakers: Rina Hui (Australia), Corey Langer (USA), Roy Herbst (USA)

Agenda
14:15 SGT	Welcome and Introductions Rina Hui
14:15 SGT	Frontline Immunotherapy Treatment Options in mNSCLC Rina Hui
14:30 SGT	Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer Roy Herbst
14:45 SGT	Choosing Immunotherapy Alone or in Combination in 1L mNSCLC Corey Langer
15:00 SGT	Q&A and Closing Remarks Rina Hui

IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the treatment of NSCLC
Date: Thursday, January 28, 2021 | Time: 15:30 - 16:30 SGT

Chairs/Speakers: Yi-Long Wu (China), Johan F. Vansteenkiste (Belgium), Yasushi Goto (Japan)

Agenda
15:30 SGT	Welcome and introduction Yi-Long Wu
15:30 SGT	Evolution of the NSCLC Treatment Landscape Yi-Long Wu
15:40 SGT	Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? Johan F. Vansteenkiste
15:55 SGT	Panel discussion All
15:07 SGT	Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target Yasushi Goto
16:21 SGT	Q&A All
16:29 SGT	Closing Yi-Long Wu

IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
Date: Thursday, January 28, 2021 | Time: 16:45 - 17:45 SGT

Chairs/Speakers: Ben Solomon (Australia), Shirish Gadgeel (USA), Solange Peters (Switzerland), Ross Soo (Singapore), Martin Rec (Germany)

Agenda
16:45 SGT	The Past, Present and Future of Biomarker-driven Advanced NSCLC Ben Solomon, Shirish Gadgeel, Solange Peters
17:15 SGT	Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer Ross Soo, Martin Reck, Solange Peters

IS08 - Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Tetsuya Mitsudomi (Japan), Byoung Chul Cho (S Korea), Enriqueta Felip (Spain)

Agenda
13:00 SGT	Welcome and introductions Tetsuya Mitsudomi
13:05 SGT	A light at the end of the tunnel Hope for patients with EGFR Exon20 insertion mutations Byoung Chul Cho
13:25 SGT	The dawn of a new era Novel treatments for patients with TKI resistant disease with common EGFR mutations Enriqueta Felip
13:45 SGT	Live Q&A: From information to transformation Navigating the evidence with experience sharing in a live forum to improve patient care All

IS09 - Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Seng Weng Wong (Singapore), John Chang (Taiwan), Thanyanan Reungwetwattana (Thailand), Nick Pavlakis (Australia), Nir Peled (Israel)

Agenda
13:00 SGT	Welcome and Introduction Seng Weng Wong
13:05 SGT	Navigating Recent Clinical Data for ALK+ TKIs Thanyanan Reungwetwattana Selecting Treatment and Management of ALK+ NSCLC Nick Pavlakis The Importance of Managing CNS disease John Chang The future of ALK+ NSCLC Nir Peled
13:45 SGT	Q&A All
13:58 SGT	Summary, Thank you and Close Seng Weng Wong

IS10 - Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Julie Brahmer (USA), Virginie Westeel (France), Nicolas Girard (France)

Agenda
13:00 SGT	Welcome and Introductions Virginie Westeel, MD, PhD
13:05 SGT	What is the role of IO in Non-metastatic NSCLC? Virginie Westeel, MD, PhD
13:20 SGT	IO in the treatment of Metastatic NSCLC, where are we now? Julie Brahmer, MD, MSc
13:35 SGT	Non-Metastatic and Metastatic NSCLC Q&A Virginie Westeel, MD, PhD Julie Brahmer, MD, MSc
13:40 SGT	What is I-O’s impact on the treatment paradigm for Mesothelioma patients? Nicolas Girard, MD
13:55 SGT	Mesothelioma Q&A and Closing Remarks Nicolas Girard, MD Virginie Westeel, MD, PhD

IS11 - Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Stephen Fox (Australia), Koichi Goto (Japan), Julie R. Brahmer (USA)

Agenda

Introductions

Current biomarker landscape in NSCLC
Stephen Fox, MBChB, DPhil

Current unmet need in KRAS G12C-mutated NSCLC
Koichi Goto, MD, PhD

Emerging novel targets for lung cancer
Julie R. Brahmer, MD, MSc

IS12 - Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: David Gandara (USA), John Gosney (UK), Barbara Melosky (Canada), Satoru Miura (Japan)

Agenda
13:00 SGT	Introduction David Gandara, MD
13:05 SGT	Know How To Test Your Patients John Gosney, MD
13:15 SGT	Know How To Sequence EGFR TKIs Barbara Melosky, MD, FRCP(C)
13:25 SGT	Know Your Patients With Uncommon EGFR Mutations Satoru Miura, MD, PhD
13:35 SGT	What’s Next For Treatment of Advanced Stage Squamous NSCLC David Gandara, MD
13:45 SGT	Know What’s Next For Your Patients: Looking to the Future David Gandara, MD
13:55 SGT	Closing David Gandara, MD

IS13 - Satellite CME Symposium Sponsored by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Daniel S.W. Tan (Singapore), Terufumi Kato (Japan), Herbert Ho Fung Loong (Hong Kong SAR)

Agenda
13:00 SGT	Welcome, introduction, and interactive quiz Daniel S.W. Tan, MD, PhD
13:05 SGT	When is the right time to use NGS-based liquid biopsy in advanced NSCLC? Herbert Ho Fung Loong, MD
13:20 SGT	Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice Terufumi Kato, MD
13:35 SGT	Enhancing immune checkpoint inhibition with bifunctional antibodies Daniel S.W. Tan, MD, PhD
13:50 SGT	Quiz questions revisited and Q&A All
13:59 SGT	Pearls for practice Daniel S.W. Tan, MD, PhD

IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
Date: Sunday, January 31, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Edward Kim (USA), Alessandro Brunelli (UK), Yoonla Choi (S Korea), Hidehito Horinouchi (Japan), Karen Reckamp (USA)

Agenda
13:00 SGT	Welcome and introduction Edward Kim
13:05 SGT	Presentation: Advances and challenges in EGFR-mutated NSCLC Edward Kim
13:15 SGT	Panel discussion: The MDT approach to managing EGFR-mutated NSCLC Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp
13:45 SGT	Audience Q&A Faculty and audience

IS15 - Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing
Date: Sunday, January 31, 2021 | Time: 13:00 – 14:00 SGT

Chairs/Speakers: Tony Mok (Hong Kong SAR), Koichi Goto (Japan), Caicun Zhou (China)

Agenda
13:00 SGT	Opening Remarks Tony Mok
13:03 SGT	Biomarker for Lung Cancer: Right Patient, Right Time, Right Test Tony Mok
13:21 SGT	Biomarker Panel Testing: PCR panel vs NGS panel Koichi Goto
13:39 SGT	Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC Caicun Zhou
13:57 SGT	Closing Remarks Tony Mok

INDUSTRY AND SATELLITE CME SYMPOSIA

Contact

Stay Connected